vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Taoping Inc. (TAOP). Click either name above to swap in a different company.

Taoping Inc. is the larger business by last-quarter revenue ($17.6M vs $11.0M, roughly 1.6× C4 Therapeutics, Inc.). Taoping Inc. runs the higher net margin — -26.6% vs -186.0%, a 159.4% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -2.6%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Taoping Inc. is a China-based technology firm providing smart cloud services, digital media solutions, and targeted internet advertising services. Its core segments cover smart city support, enterprise digital transformation tools, and offline new retail digital operations, serving mainly enterprise and public sector clients in the domestic market.

CCCC vs TAOP — Head-to-Head

Bigger by revenue
TAOP
TAOP
1.6× larger
TAOP
$17.6M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+115.4% gap
CCCC
112.8%
-2.6%
TAOP
Higher net margin
TAOP
TAOP
159.4% more per $
TAOP
-26.6%
-186.0%
CCCC

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
CCCC
CCCC
TAOP
TAOP
Revenue
$11.0M
$17.6M
Net Profit
$-20.5M
$-4.7M
Gross Margin
10.1%
Operating Margin
-210.1%
-23.8%
Net Margin
-186.0%
-26.6%
Revenue YoY
112.8%
-2.6%
Net Profit YoY
40.7%
-894.8%
EPS (diluted)
$-0.09
$-6.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
TAOP
TAOP
Q4 25
$11.0M
Q3 25
$11.2M
Q2 25
$6.5M
$17.6M
Q1 25
$7.2M
Q4 24
$5.2M
$18.6M
Q3 24
$15.4M
Q2 24
$12.0M
$18.1M
Q1 24
$3.0M
Net Profit
CCCC
CCCC
TAOP
TAOP
Q4 25
$-20.5M
Q3 25
$-32.2M
Q2 25
$-26.0M
$-4.7M
Q1 25
$-26.3M
Q4 24
$-34.6M
$-2.4M
Q3 24
$-24.7M
Q2 24
$-17.7M
$588.7K
Q1 24
$-28.4M
Gross Margin
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
Q2 25
10.1%
Q1 25
Q4 24
19.5%
Q3 24
Q2 24
22.9%
Q1 24
Operating Margin
CCCC
CCCC
TAOP
TAOP
Q4 25
-210.1%
Q3 25
-306.4%
Q2 25
-441.0%
-23.8%
Q1 25
-402.9%
Q4 24
-728.4%
-8.0%
Q3 24
-183.9%
Q2 24
-178.6%
-0.7%
Q1 24
-1060.2%
Net Margin
CCCC
CCCC
TAOP
TAOP
Q4 25
-186.0%
Q3 25
-286.4%
Q2 25
-402.6%
-26.6%
Q1 25
-363.7%
Q4 24
-667.8%
-13.0%
Q3 24
-160.6%
Q2 24
-147.6%
3.3%
Q1 24
-933.2%
EPS (diluted)
CCCC
CCCC
TAOP
TAOP
Q4 25
$-0.09
Q3 25
$-0.44
Q2 25
$-0.37
$-6.54
Q1 25
$-0.37
Q4 24
$-0.50
$-3.58
Q3 24
$-0.35
Q2 24
$-0.26
$3.29
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
TAOP
TAOP
Cash + ST InvestmentsLiquidity on hand
$74.6M
$2.2M
Total DebtLower is stronger
$5.8M
Stockholders' EquityBook value
$256.6M
$14.5M
Total Assets
$359.1M
$30.3M
Debt / EquityLower = less leverage
0.40×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
TAOP
TAOP
Q4 25
$74.6M
Q3 25
$58.8M
Q2 25
$78.2M
$2.2M
Q1 25
$51.3M
Q4 24
$55.5M
$1.6M
Q3 24
$59.6M
Q2 24
$73.1M
$480.3K
Q1 24
$89.7M
Total Debt
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
Q2 25
$5.8M
Q1 25
Q4 24
$5.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CCCC
CCCC
TAOP
TAOP
Q4 25
$256.6M
Q3 25
$154.4M
Q2 25
$174.1M
$14.5M
Q1 25
$195.1M
Q4 24
$216.0M
$15.9M
Q3 24
$242.7M
Q2 24
$247.1M
$15.8M
Q1 24
$258.3M
Total Assets
CCCC
CCCC
TAOP
TAOP
Q4 25
$359.1M
Q3 25
$265.5M
Q2 25
$296.5M
$30.3M
Q1 25
$319.5M
Q4 24
$349.6M
$35.1M
Q3 24
$376.1M
Q2 24
$381.1M
$34.1M
Q1 24
$398.4M
Debt / Equity
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
Q2 25
0.40×
Q1 25
Q4 24
0.37×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
TAOP
TAOP
Operating Cash FlowLast quarter
$-22.1M
$-1.5M
Free Cash FlowOCF − Capex
$-2.8M
FCF MarginFCF / Revenue
-16.0%
Capex IntensityCapex / Revenue
7.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
TAOP
TAOP
Q4 25
$-22.1M
Q3 25
$-31.2M
Q2 25
$-12.1M
$-1.5M
Q1 25
$-33.3M
Q4 24
$-17.9M
$147.4K
Q3 24
$-24.1M
Q2 24
$-5.0M
$-2.5M
Q1 24
$-18.1M
Free Cash Flow
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
$-31.6M
Q2 25
$-2.8M
Q1 25
Q4 24
$-17.9M
$-129.3K
Q3 24
$-24.1M
Q2 24
$-5.2M
$-3.3M
Q1 24
FCF Margin
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
-281.5%
Q2 25
-16.0%
Q1 25
Q4 24
-346.5%
-0.7%
Q3 24
-157.2%
Q2 24
-43.1%
-18.3%
Q1 24
Capex Intensity
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
3.7%
Q2 25
7.6%
Q1 25
Q4 24
0.1%
1.5%
Q3 24
0.1%
Q2 24
1.6%
4.3%
Q1 24
0.0%
Cash Conversion
CCCC
CCCC
TAOP
TAOP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-4.30×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons